Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
- Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
- Roche response to COVID-19 pandemic
- AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
- Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
Research & Development
- Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19
- CAR macrophages go beyond T cells to fight solid tumors
- Vivli to launch a portal for sharing data from COVID-19 trials
- Understanding how COVID-19 affects children vital to slowing pandemic
- Favipiravir flu drug 'clearly effective' in treating COVID-19
- COVID-19: The immune system can fight back
- New kind of CRISPR technology to target RNA, including RNA viruses like coronavirus
Conferences & Events
- The COVID-19 coronavirus epidemic has a natural origin
- Pre-Filled Syringes West Coast 2020
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
- SMi's 20th Annual Pain Therapeutics Conference 2020
- SMi's 3rd Annual Pharmaceutical Microbiology East Coast
- SMi's 22nd Annual Superbugs & Superdrugs Conference 2020
Regulatory Affairs
- The FDA is facilitating access to convalescent plasma collected from recovered COVID-19 patients
- FDA continues to facilitate development of COVID-19 treatments
- FDA and FTC warn seven companies selling fraudulent products that claim to treat or prevent COVID-19
- FDA approves new treatment for adults with Cushing's disease
- FDA approves first generic of Daraprim